Serina Therapeutics Secures $10 Million for Parkinson’s Trials

Categories: Business NewsHealthcareNewsPharmaceutical

Scientists working on Parkinson's disease treatments in a lab

Article Sponsored by:

SPACE AVAILABLE FOR SPONSORS!

Want to target the right audience? Sponsor our site and choose your specific industry to connect with a relevant audience.

What Sponsors Receive:

Prominent brand mentions across targeted, industry-focused articles
High-visibility placements that speak directly to an engaged local audience
Guaranteed coverage that maximizes exposure and reinforces your brand presence

Interested in seeing what sponsored content looks like on our platform?

Browse Examples of Sponsored News and Articles:

May’s Roofing & Contracting
Forwal Construction
NSC Clips
Real Internet Sales
Suited
Florida4Golf

Click the button below to sponsor our articles:

Sponsor Our Articles

News Summary

Serina Therapeutics has secured a significant funding boost of $10 million from JuvVentures to initiate clinical trials for a novel Parkinson’s disease treatment. Utilizing their proprietary POZ Platform™, the company aims to improve drug delivery and efficacy for patients. Clinical trials are set to begin in late 2025, offering renewed hope for advanced Parkinson’s disease management. This investment marks a pivotal moment for Serina, highlighting its potential role in advancing neurological health solutions.

Exciting News from Huntsville: Serina Therapeutics Secures $10 Million for Parkinson’s Disease Trials!

Huntsville, Alabama, is buzzing with excitement as Serina Therapeutics has clinched a significant funding boost of $10 million. This fresh capital comes courtesy of JuvVentures, a UK-based investor with a keen interest in groundbreaking medical solutions. So, what does all this mean? Get ready for some fantastic news on a new drug delivery method for those battling advanced Parkinson’s disease!

Time to Kick Off Clinical Trials!

With this funding, Serina is gearing up to begin clinical trials in the second half of 2025. That’s not too far away, and it brings a wave of hope to Parkinson’s patients who are seeking better treatment options. These trials will test a novel approach to delivering a well-known Parkinson’s medication, apomorphine, making it not just easier to use but also more effective!

Breaking Down the Technology

So, how exactly is Serina planning to enhance the treatment? They’re employing their own cutting-edge technology, which they call the POZ Platform™. This platform allows for better control over how the drug is loaded and released, which could lead to improvements in how the medication works in the body. It’s all about providing that critical continuous dopaminergic stimulation (CDS) that patients need to minimize the unpleasant motor fluctuations often experienced with traditional treatments.

But that’s not all! Serina is teaming up with Enable Injections to create a wearable delivery device. This nifty gadget is designed to make administering apomorphine a breeze, offering long-acting subcutaneous injections without the hassles of skin irritation that can sometimes occur with other delivery methods. The goal here is to ensure that patients have access to their medication in a way that promotes both comfort and compliance.

Investing in the Future of Neurological Health

This $10 million funding agreement marks an important milestone for Serina Therapeutics and is expected to help them chart a path towards advancing new therapies for neurological diseases. The funding includes issuing one million shares at $10 per share, which reflects a 120% premium over the recent closing price. With the first half of this funding already received on November 27, 2024, the team at Serina is focused and ready to go!

Serina’s Financial Standing

The company, whose roots are nestled in the fascinating HudsonAlpha Institute of Biotechnology campus, shared its financial results for the third quarter. While the revenues primarily came from NIH grants, they also faced some challenges with increasing operational expenses. As of the end of September 2024, Serina had approximately $3.2 million in cash and equivalents, which raised some eyebrows regarding their financial future and ability to meet upcoming obligations. However, with this new funding, there is a renewed sense of optimism.

What’s Next?

Looking ahead, the clinical trials for SER-252 (the POZ-apomorphine combination) could mark a pivotal moment in how advanced Parkinson’s disease is treated, potentially steering patients away from complicated regimens that are less effective. As the world watches this innovative company, the citizens of Huntsville can take pride in knowing that their local biotech scene is at the forefront of medical advancement.

In summary, the exciting developments at Serina Therapeutics illustrate a bright path forward in the battle against Parkinson’s disease, combining technology and compassion in the quest for better treatment. Here’s hoping for a future filled with groundbreaking changes!